推荐产品
品質等級
物種活性
mouse
製造商/商標名
Milliplex®
assay range
accuracy: 73-98%
sensitivity: 0.001-0.041 ng/mL
(MinDC+2SD)
standard curve range: 0.001-1 ng/mL
(VEGF)
standard curve range: 0.005-5 ng/mL
(IP-10)
standard curve range: 0.01-15 ng/mL
(KIM-1)
standard curve range: 0.02-25 ng/mL
(TIMP-1)
standard curve range: 0.05-50 ng/mL
(β-2-Microglobulin)
standard curve range: 0.05-50 ng/mL
(Renin)
技術
multiplexing: suitable
檢測方法
fluorometric (Luminex xMAP)
運輸包裝
wet ice
一般說明
MILLIPLEX®小鼠肾损伤珠组套1包含使用Luminex® xMAP®技术以任何组合测量以下六个生物标志物所需的所有组件: β-2-微球蛋白、IP-10、KIM-1、肾素、TIMP-1、VEGF。该试剂盒使用96孔格式,包含冻干标准混合物,两个对照品,可以一式两份测量多达38份尿液样品。
應用
- 分析物:β-2-微球蛋白、IP-10、KIM-1、肾素TIMP-1、VEGF
- 建议样品类型:尿液
- 建议样品稀释度:1:25
- 测定运行时间:过夜
- 研究类别:毒性
特點和優勢
通过在此组套中选择可用的分析物来设计多重试剂盒。
其他說明
灵敏度:请参阅试剂盒方案了解单个检测试剂盒的灵敏度。
请联系技术服务部了解稀释线性。
法律資訊
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
標靶器官
Respiratory Tract
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Biomolecules, 12(2) (2022-02-26)
BMAL1 is a core mammalian circadian clock transcription factor responsible for the regulation of the expression of thousands of genes. Previously, male skeletal-muscle-specific BMAL1-inducible-knockout (iMS-BMAL1 KO) mice have been described as a model that exhibits an aging-like phenotype with an
Journal of Alzheimer's disease : JAD, 60(2), 461-481 (2017-09-05)
Hyperphosphorylation and aggregation of tau protein is a critical factor in many neurodegenerative diseases. These diseases are increasing in prevalence, and there are currently no cures. Previous work from our group and others has shown that tyrosine kinase inhibitors (TKIs)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门